DSpace Repository

Autologous stem cell transplantation and stem cell mobilization kinetics

Show simple item record

dc.contributor.author Dogu, MH
dc.contributor.author Cagirgan, S
dc.contributor.author Ocakci, S
dc.contributor.author Kaya, AH
dc.contributor.author Ilkkilic, K
dc.contributor.author Sanli, NM
dc.contributor.author Kahraman, S
dc.contributor.author Eren, R
dc.contributor.author Tekgunduz, E
dc.contributor.author Hacioglu, S
dc.contributor.author Kaynar, L
dc.contributor.author Erkurt, MA
dc.contributor.author Altuntas, F
dc.date.accessioned 2022-10-13T10:45:47Z
dc.date.available 2022-10-13T10:45:47Z
dc.date.issued 2017
dc.identifier.uri http://hdl.handle.net/11616/78199
dc.description.abstract As known, the world population is aging and as the life span increases the number of advanced-age lymphomas also shows an upward trend. Autologous hematopoietic stem cell transplantation (HSCT) is the standard treatment modality in chemotherapy-sensitive relapsed or refractory aggressive lymphomas. Increased morbidity and mortality related to both the transplant itself and comorbid diseases can be observed in elderly lymphoma patients. Patients who are 65 years or older and underwent autologous HSCT with B-cell non-Hodgkin lymphoma were retrospectively included in our study. In terms of survival analysis, median follow-up was 34.5 months (8-159) while the overall survival (OS) was 58%. In the univariate analysis of prognostic data in OS, patients who were referred to transplantation with complete response had a statistically significant survival advantage (p=0.043). In terms of the effect of pre-transplant conditioning regimens on survival, BEAM regimen yielded better results, though not statistically significant. Age, number of chemotherapy cycles received before mobilization and radiation therapy had no significant effect on the CD34 (+) cell count in the final product (p = 0.492, 0.746 and 0.078 respectively). In conclusion, autologous HSCT is a practicable treatment modality that provides survival advantage in suitable advanced-age patients with a diagnosis of B-cell non-Hodgkin lymphoma. (C) 2017 Elsevier Ltd. All rights reserved.
dc.description.abstract C1 [Dogu, Mehmet Hilmi; Eren, Rafet] Istanbul Training & Res Hosp, Hematol Clin, TR-34098 Istanbul, Turkey.
dc.description.abstract [Cagirgan, Seckin; Ocakci, Serkan; Kahraman, Selda] Med Pk Izmir Hosp, Dept Hematol, Izmir, Turkey.
dc.description.abstract [Kaya, Ali Hakan; Tekgunduz, Emre; Altuntas, Fevzi] Ankara Oncol Training & Res Hosp, Hematol & Stem Cell Transplantat Clin, Ankara, Turkey.
dc.description.abstract [Ilkkilic, Kadir; Hacioglu, Sibel] Pamukkale Univ, Fac Med, Dept Hematol, Denizli, Turkey.
dc.description.abstract [Sanli, Neslihan Mandaci; Kaynar, Leylagul] Erciyes Univ, Fac Med, Dept Hematol, Kayseri, Turkey.
dc.description.abstract [Erkurt, Mehmet Ali] Inonu Univ, Dept Hematol, Fac Med, Malatya, Turkey.
dc.description.abstract [Altuntas, Fevzi] Yildirim Beyazit Univ, Fac Med, Dept Hematol, Ankara, Turkey.
dc.source TRANSFUSION AND APHERESIS SCIENCE
dc.title Autologous stem cell transplantation and stem cell mobilization kinetics
dc.title in elderly patients with B cell non-Hodgkin lymphoma


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record